All In Biotech

Drug Trial Radar · NCT07195175

Study of MAR002 in Healthy Men

First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Marea TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Conditions

  • Acromegaly

Interventions

  • MAR002Drug

    subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with TEAEs (treatment-emergent adverse events)Time frame: From first dose of study drug through final End of Study/Early Termination Visit. End of Study is Day 64 for Cohorts 1 and 2; End of Study is day 169 for Cohorts 3, 4, 5, and 6.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Marea Site

    Tempe, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.